 |  |
With a presence in Singapore since 2002, Lilly Singapore Centre for Drug Discovery (LSCDD) is focused on cancer biomarker discovery, drug discovery in the areas of cancer and diabetes and integrative computational sciences.
A key area for drug discovery efforts at LSCDD is the development of therapeutics that modulate epigenetic drug targets. Epigenetic targets form a novel, very promising and exciting class of targets involved in
gene-regulation mechanisms underlying diseases such as cancer and diabetes. | |
